Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its first full week after launch, surpassing other GLP-1 starts. Investors eye its edge over Eli Lilly in the competitive obesity market. Oral treatments offer needle-free flexibility for patients.
Novo Nordisk's Wegovy pill achieved 18,410 U.S. prescriptions in the first full week following its January 5 launch, according to IQVIA data shared by an analyst.
The pill reached 3,071 prescriptions in the initial four days. "We note this is tracking ahead of other GLP-1 launches," Guggenheim analysts stated in a research note.
Track your medication journey
Join thousands using Shotlee to track GLP-1 medications.
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!
Investors monitor prescription trends closely as Novo seeks to leverage its first-mover advantage against Eli Lilly in the booming weight-loss sector. Under new CEO Mike Doustdar, who assumed leadership last year, Novo aims to attract new users with this blockbuster treatment's pill form amid prior sales slowdowns.
Novo's shares climbed 25% in January, rising 2.5% on Friday to a high not seen since late July.
Original source: Pulse24.com
View original article →Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.
Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.
Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.
